We still don’t have a reliable test to diagnose long COVID, according to international researchers who looked at a trial of more than 10,000 adult patients investigating COVID-19 and long COVID. The team compared questionnaire responses and routine clinical lab results to figure out if COVID-19 infection led to abnormalities in these tests. They found that those with prior COVID-19 infection had more test results that usually point to early kidney disease associated with heart disease, and also evidence to support heightened diabetes risk. The team also found ongoing inflammation could potentially be an underlying contributor to anosmia (lost of taste/smell) and long COVID. However, none of the 25 routine lab results in the study could be clinically useful to figure out if someone was suffering from long COVID. An accompanying editorial says some of the greatest unsolved challenges of the COVID-19 pandemic relate to understanding, diagnosing, and treating long COVID.
Journal/conference: Annals of Internal Medicine
Link to research (DOI): 10.7326/M24-0892
Organisation/s: University of Colorado, USA
Funder: This research was funded by the National Institutes
of Health Agreements OTA OT2HL161847, OT2HL161841, and
OT2HL156812 as part of the RECOVER Research Initiative and R01
HL162373.
Media release
From: American College of Physicians
1. “Long COVID” continues to evade diagnosisOf 25 routine clinical lab tests, not one can aid in diagnosing post-acute sequelae of SARS-CoV-2A national cohort study of adult participants with and without prior SARS-CoV-2 infection found that there are no objective tests to accurately diagnose post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Data also suggested that many of the long-term PASC symptoms are due to ongoing inflammation, rather than viral invasion of the affected area. The findings are published in Annals of Internal Medicine.Researchers from the National Institutes of Health studied more than 10,000 adult patients enrolled in the RECOVER (Researching COVID to Enhance Recovery) trial to investigate clinical laboratory markers of SARS-CoV-2 and PASC. Because a baseline was necessary to compare variables, adults were eligible to participate in the study regardless of prior infection of SARS-CoV-2. The researchers compared questionnaire responses and routine clinical laboratory results from participants to determine if SARS-CoV-2 led to persistent laboratory abnormalities, whether or not symptoms were present. The researchers found that none of the 25 routine clinical laboratory values assessed in the study could serve as a clinically useful biomarker of PASC. Additionally, they found evidence to support the idea that SARS-CoV-2 may contribute to diabetes risk independent of PASC symptoms, a connection that had been made early in the pandemic. Those with prior SARS-CoV-2 also had higher urine albumin to creatinine ratio, a marker of early kidney disease that has been associated with cardiovascular disease in other populations. The data also showed that ongoing inflammation is a potential mechanism underlying anosmia (smell/taste disturbances) and PASC.The authors of an accompanying editorial from Johns Hopkins University say that some of the greatest unsolved challenges of the COVID pandemic relate to understanding, diagnosing, and treating long COVID. Extremely large observational studies like RECOVER are a once-in-a-lifetime opportunity to study an infection-associated chronic illness that occurred simultaneously in millions triggered by the same pathogen. The findings are a reminder that physicians should consider long COVID in differential diagnoses for symptoms or conditions without apparent etiology.
American College of Physicians
Web page
American College of Physicians
Web page